SCHEMBL5111558

SCHEMBL5111558

O=C(NCCOc1ccc(F)cc1)Nc1cccc2c1C[C@H](O)CC2

nearest known ligand 0.49

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 18/20 0.49
LMNA P02545 1/20 0.41
OPRM1 P35372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118025 1.00 TRPV1 (0.49) TRPV1LMNAOPRM1
SCHEMBL5105662 1.00 TRPV1 (0.49) TRPV1LMNAOPRM1
SCHEMBL5109897 0.87 RAB9A (0.50) TRPV1LMNAOPRM1
SCHEMBL5111003 0.85 TRPV1 (0.53) TRPV1OPRM1
SCHEMBL5558143 0.84 TRPV1 (0.46) TRPV1LMNAOPRM1
SCHEMBL5111925 0.83 LMNA (0.51) TRPV1LMNA
SCHEMBL13627960 0.82 TRPV1 (0.46) TRPV1LMNAOPRM1
SCHEMBL13613612 0.82 TRPV1 (0.55) TRPV1LMNAOPRM1
SCHEMBL5109705 0.80 TRPV1 (0.43) TRPV1LMNAOPRM1
SCHEMBL2734531 0.80 TRPV1 (0.53) TRPV1LMNAOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423175-B2 Hydroxy-tetrahydro-naphthalenylurea derivatives BAYER HEALTHCARE AG (DE) 2008-09-09 US claimed
EP-1594836-B1 HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2007-09-19 EP claimed
US-20070027187-A1 Hydroxy-tetrahydro-naphthalenylurea derivatives BAYER HEALTHCARE AG (DE) 2007-02-01 US claimed
EP-1594836-A1 HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES Bayer HealthCare AG (DE) 2005-11-16 EP claimed
WO-2004072020-A1 HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-08-26 WO claimed
US-7423175-B2 Hydroxy-tetrahydro-naphthalenylurea derivatives BAYER HEALTHCARE AG (DE) 2008-09-09 US disclosed
US-7423175-B2 Hydroxy-tetrahydro-naphthalenylurea derivatives BAYER HEALTHCARE AG (DE) 2008-09-09 US disclosed
US-7423175-B2 Hydroxy-tetrahydro-naphthalenylurea derivatives BAYER HEALTHCARE AG (DE) 2008-09-09 US disclosed
EP-1594836-B1 HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2007-09-19 EP disclosed
EP-1594836-B1 HYDROXY-TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES BAYER HEALTHCARE AG (DE) 2007-09-19 EP disclosed
US-20070027187-A1 Hydroxy-tetrahydro-naphthalenylurea derivatives BAYER HEALTHCARE AG (DE) 2007-02-01 US disclosed
US-20070027187-A1 Hydroxy-tetrahydro-naphthalenylurea derivatives BAYER HEALTHCARE AG (DE) 2007-02-01 US disclosed
US-20070027187-A1 Hydroxy-tetrahydro-naphthalenylurea derivatives BAYER HEALTHCARE AG (DE) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027187-A1 Hydroxy-tetrahydro-naphthalenylurea derivatives HVCN1, NMUR1, OPRL1 TRPV1 31/4885LMNA 3474/4885OPRM1 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.